
MAZE Stock Forecast & Price Target
MAZE Analyst Ratings
Bulls say
Maze Therapeutics is supported by a diversified, genetics-driven pipeline in CKD and related metabolic disease, with MZE829 offering the most important near-term catalyst through updated HORIZON data in late-2026 and early-2027. The recent VRTX APOL1 readout is viewed as de-risking for MZE829 because it supports proteinuria reduction beyond FSGS and highlights a potential safety edge, while Maze has not reported liver enzyme elevations and notes greater in vitro potency versus inaxaplin. The balance sheet also supports the thesis, with current cash providing runway beyond near-term proof-of-concept readouts, while MZE782 and its Phase 2 CIPheR study add a second shot on goal and a valuation floor ahead of 2027 updates.
Bears say
Maze Therapeutics is vulnerable to fundamental risks that weaken the case for the stock, including regulatory uncertainty, execution risk, and a competitive landscape already populated by branded players such as VRTX and Otsuka alongside generic rivals. The company’s reliance on accelerated approval pathways could still require additional or longer studies, and any failure to secure favorable labels could limit market traction. It is also expected to need additional external funding to advance its platform, so limited access to capital markets could delay or even terminate development campaigns.
This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MAZE Analyst Forecast & Price Prediction
Start investing in MAZE
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Maze Therapeutics Inc (MAZE) Forecast
MAZE Analyst Forecast & Price Prediction
Start investing in MAZE
Order type
Buy in
Order amount
Est. shares
0 shares